Digestive Diseases and Sciences

, Volume 56, Issue 5, pp 1266–1281 | Cite as

The Management of Hospitalized Patients with Cirrhosis: The Mount Sinai Experience and a Guide for Hospitalists

  • Ponni V. Perumalswami
  • Thomas D. SchianoEmail author



Cirrhosis and chronic liver disease carry appreciable morbidity and mortality. Cirrhotic patients frequently require hospitalization and their care is both extremely complex and labor-intensive.


We seek to provide a review for gastroenterologists, hepatologists, internists, and hospitalists on the approach to care in patients hospitalized for complications related to end-stage liver disease.


The Mount Sinai Medical Center’s inpatient liver service has developed an integrated team approach for cirrhotic patients and throughout the years has educated fellows-in-training and medical house staff on both the treatment principles and “pearls” in managing the hospitalized cirrhotic patient. We reviewed the literature and provide recommendations on the management of complications of end-stage liver disease. Additionally, we provide a review of the protocols used at our institution in the care for cirrhotic patients.


Major complications of advanced liver disease include infection, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, portal hypertension, variceal hemorrhage, hepatorenal syndrome, and hepatocellular carcinoma. Management of these complications involves selecting the appropriate diagnostic studies and prompt administration of therapy.


There are many complications of cirrhosis. Management of these complications can be complex and are targeted at stabilizing the patient’s clinical condition. Liver transplantation remains the only definitive treatment.


Hospitalization Hospitalist Cirrhosis Management End-stage liver disease 



We would like to acknowledge all the attending staff of the Mount Sinai Division of Liver Diseases, a generation of hepatology fellows, medical housestaff, nurses, and ancillary staff who continue to provide exemplary care to our patients suffering from chronic liver disease.


  1. 1.
    Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53:1–115.PubMedGoogle Scholar
  2. 2.
    DeFrances CJ, Cullen KA, Kozak LJ. National hospital discharge survey: 2005 Annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2007;13:24.Google Scholar
  3. 3.
    Falagas ME, Vardakas KZ, Vergidis PI. Under-diagnosis of common chronic diseases: prevalence and impact on human health. Int J Clin Pract. 2007;61:1569–1579.PubMedGoogle Scholar
  4. 4.
    Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38:S38–S53.PubMedGoogle Scholar
  5. 5.
    Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30–S34.PubMedGoogle Scholar
  6. 6.
    Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559–568, vi–vii.Google Scholar
  7. 7.
    Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992;327:1906–1911.PubMedGoogle Scholar
  8. 8.
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–338.PubMedGoogle Scholar
  9. 9.
    Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51:729–733.PubMedGoogle Scholar
  10. 10.
    United Network of Organ Sharing (UNOS). UNOS database.Google Scholar
  11. 11.
    Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–817.PubMedGoogle Scholar
  12. 12.
    Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210–215.PubMedGoogle Scholar
  13. 13.
    Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22:83–96.PubMedGoogle Scholar
  14. 14.
    Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis. 2010;30:186–194.PubMedGoogle Scholar
  15. 15.
    Tripodi A, Baglin T, Robert A, et al. Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease. J Thromb Haemost. 2010;8:1410–1412.PubMedGoogle Scholar
  16. 16.
    Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52:605–613.PubMedGoogle Scholar
  17. 17.
    Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84:170–179.PubMedGoogle Scholar
  18. 18.
    Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184.PubMedGoogle Scholar
  19. 19.
    Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592.PubMedGoogle Scholar
  20. 20.
    Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000.PubMedGoogle Scholar
  21. 21.
    Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med. 1995;332:1192–1197.PubMedGoogle Scholar
  22. 22.
    Sauer P, Theilmann L, Stremmel W, Benz C, Richter GM, Stiehl A. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology. 1997;113:1623–1631.PubMedGoogle Scholar
  23. 23.
    Lind CD, Malisch TW, Chong WK, et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. Gastroenterology. 1994;106:1277–1283.PubMedGoogle Scholar
  24. 24.
    Hausegger KA, Sternthal HM, Klein GE, Karaic R, Stauber R, Zenker G. Transjugular intrahepatic portosystemic shunt: angiographic follow-up and secondary interventions. Radiology. 1994;191:177–181.PubMedGoogle Scholar
  25. 25.
    Forster J, Siegel EL, Delcore R, Payne KM, Laurin J, Kindscher JD. Is the role of transjugular intrahepatic portosystemic shunts limited in the management of patients with end-stage liver disease? Am J Surg. 1996;172:536–539; discussion 539-40.Google Scholar
  26. 26.
    Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27:742–747.PubMedGoogle Scholar
  27. 27.
    Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–475.PubMedGoogle Scholar
  28. 28.
    Kovacs A, Schepke M, Heller J, Schild HH, Flacke S. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: preliminary results. Cardiovasc Intervent Radiol. 2010;33:290–296.PubMedGoogle Scholar
  29. 29.
    Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2736–2741.PubMedGoogle Scholar
  30. 30.
    Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–674.PubMedGoogle Scholar
  31. 31.
    Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163–2182.PubMedGoogle Scholar
  32. 32.
    Teran JC. Nutrition and liver diseases. Curr Gastroenterol Rep. 1999;1:335–340.PubMedGoogle Scholar
  33. 33.
    Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005;12:133–141.PubMedGoogle Scholar
  34. 34.
    Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85:451–458.PubMedGoogle Scholar
  35. 35.
    Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17:530–548.PubMedGoogle Scholar
  36. 36.
    Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of patients with cirrhosis who are discharged from the hospital against medical advice. Clin Gastroenterol Hepatol. 2009;7:786–792.PubMedGoogle Scholar
  37. 37.
    Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality 4-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–1256.PubMedGoogle Scholar
  38. 38.
    Vollberg CM, Herrera JL. Vibrio vulnificus infection: an important cause of septicemia in patients with cirrhosis. South Med J. 1997;90:1040–1042.PubMedGoogle Scholar
  39. 39.
    Ko WC, Chuang YC, Huang GC, Hsu SY. Infections due to non-O1 Vibrio cholerae in southern Taiwan: predominance in cirrhotic patients. Clin Infect Dis. 1998;27:774–780.PubMedGoogle Scholar
  40. 40.
    Feldman M, Friedman LS, Brandt LJ. Section 9: Liver. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 8th ed. Philadelphia: Elsevier Health Sciences; 2006:1937.Google Scholar
  41. 41.
    Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008;48:1002–1010.PubMedGoogle Scholar
  42. 42.
    Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939.PubMedGoogle Scholar
  43. 43.
    Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204–213.PubMedGoogle Scholar
  44. 44.
    Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–148.PubMedGoogle Scholar
  45. 45.
    Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32:142–153.PubMedGoogle Scholar
  46. 46.
    Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon. 1985;31:1–48.PubMedGoogle Scholar
  47. 47.
    Song JY, Jung SJ, Park CW, et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired. J Korean Med Sci. 2006;21:666–671.PubMedGoogle Scholar
  48. 48.
    Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol. 2001;96:1232–1236.PubMedGoogle Scholar
  49. 49.
    Kerr DN, Pearson DT, Read AE. Infection of ascitic fluid in patients with hepatic cirrhosis. Gut. 1963;4:394–398.PubMedGoogle Scholar
  50. 50.
    Conn HO. Spontaneous peritonitis and bacteremia in Laennec’s cirrhosis caused by enteric organisms. A relatively common but rarely recognized syndrome. Ann Intern Med. 1964;60:568–580.PubMedGoogle Scholar
  51. 51.
    Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8:27–31.PubMedGoogle Scholar
  52. 52.
    Garcia-Tsao G. Spontaneous bacterial peritonitis: a historical perspective. J Hepatol. 2004;41:522–527.PubMedGoogle Scholar
  53. 53.
    Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20:1495–1501.PubMedGoogle Scholar
  54. 54.
    Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409.PubMedGoogle Scholar
  55. 55.
    Cales P, Zabotto B, Meskens C, et al. Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology. 1990;98:156–162.PubMedGoogle Scholar
  56. 56.
    D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995;22:332–354.PubMedGoogle Scholar
  57. 57.
    Jamal MM, Samarasena JB, Hashemzadeh M. Decreasing in-hospital mortality for oesophageal variceal hemorrhage in the USA. Eur J Gastroenterol Hepatol. 2008;20:947–955.PubMedGoogle Scholar
  58. 58.
    McCormick PA, O’Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut. 2001;49:682–685.PubMedGoogle Scholar
  59. 59.
    Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800–809.PubMedGoogle Scholar
  60. 60.
    Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut. 2005;54:556–563.PubMedGoogle Scholar
  61. 61.
    Garcia-Pagan JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology. 2001;121:908–914.PubMedGoogle Scholar
  62. 62.
    ASGE STANDARDS OF PRACTICE COMMITTEE, Banerjee S, Shen B, et al. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67:791–798.PubMedGoogle Scholar
  63. 63.
    Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573–577.PubMedGoogle Scholar
  64. 64.
    Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion. 2001;41:1244–1248.PubMedGoogle Scholar
  65. 65.
    Weber JG, Warner MA, Moore SB. What is the incidence of perioperative transfusion-related acute lung injury? Anesthesiology. 1995;82:789.PubMedGoogle Scholar
  66. 66.
    Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion. 1992;32:589–592.PubMedGoogle Scholar
  67. 67.
    Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101:454–462.PubMedGoogle Scholar
  68. 68.
    Menitove JE. Transfusion related acute lung injury (TRALI): a review. Mo Med. 2007;104:270–275.PubMedGoogle Scholar
  69. 69.
    Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B. Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol. 2009;15:1459–1464.PubMedGoogle Scholar
  70. 70.
    Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96–101.PubMedGoogle Scholar
  71. 71.
    Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology. 1996;23:1041–1046.PubMedGoogle Scholar
  72. 72.
    Muller MJ, Lautz HU, Plogmann B, Burger M, Korber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology. 1992;15:782–794.PubMedGoogle Scholar
  73. 73.
    Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602–609.PubMedGoogle Scholar
  74. 74.
    Figueiredo FA, Dickson ER, Pasha TM, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl. 2000;6:575–581.PubMedGoogle Scholar
  75. 75.
    Roongpisuthipong C, Sobhonslidsuk A, Nantiruj K, Songchitsomboon S. Nutritional assessment in various stages of liver cirrhosis. Nutrition. 2001;17:761–765.PubMedGoogle Scholar
  76. 76.
    Davidson HI, Richardson R, Sutherland D, Garden OJ. Macronutrient preference, dietary intake, and substrate oxidation among stable cirrhotic patients. Hepatology. 1999;29:1380–1386.PubMedGoogle Scholar
  77. 77.
    Richardson RA, Davidson HI, Hinds A, Cowan S, Rae P, Garden OJ. Influence of the metabolic sequelae of liver cirrhosis on nutritional intake. Am J Clin Nutr. 1999;69:331–337.PubMedGoogle Scholar
  78. 78.
    Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445–450.PubMedGoogle Scholar
  79. 79.
    Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation. 1994;57:469–472.PubMedGoogle Scholar
  80. 80.
    Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E, Muller MJ. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology. 1997;25:652–657.PubMedGoogle Scholar
  81. 81.
    Muller MJ, Lautz HU, Plogmann B, Burger M, Korber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology. 1992;15:782–794.PubMedGoogle Scholar
  82. 82.
    Harrison J, McKiernan J, Neuberger JM. A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. Transpl Int. 1997;10:369–374.PubMedGoogle Scholar
  83. 83.
    Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med. 1999;107:262–267.PubMedGoogle Scholar
  84. 84.
    Xiol X, Guardiola J. Hepatic hydrothorax. Curr Opin Pulm Med. 1998;4:239–242.PubMedGoogle Scholar
  85. 85.
    Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med. 2003;9:261–265.PubMedGoogle Scholar
  86. 86.
    Liu LU, Haddadin HA, Bodian CA, et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest. 2004;126:142–148.PubMedGoogle Scholar
  87. 87.
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156.PubMedGoogle Scholar
  88. 88.
    Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S169–S171.PubMedGoogle Scholar
  89. 89.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750.PubMedGoogle Scholar
  90. 90.
    Taylor-Robinson SD, Thomas HC, Arora S, Hargreaves S. Increased mortality from liver cancer in England and Wales is not related to hepatitis C. BMJ. 1999;319:640.PubMedGoogle Scholar
  91. 91.
    Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–813.PubMedGoogle Scholar
  92. 92.
    El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227–3230.PubMedGoogle Scholar
  93. 93.
    Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240:900–909.PubMedGoogle Scholar
  94. 94.
    Fontana RJ, Hamidullah H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165–1174.PubMedGoogle Scholar
  95. 95.
    Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36:687–691.PubMedGoogle Scholar
  96. 96.
    Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179–S188.PubMedGoogle Scholar
  97. 97.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.PubMedGoogle Scholar
  98. 98.
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.PubMedGoogle Scholar
  99. 99.
    Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005;80:S113–S119.PubMedGoogle Scholar
  100. 100.
    Bruix J, Sherman M. Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.PubMedGoogle Scholar
  101. 101.
    Blei AT, Cordoba J. Practice parameters committee of the American college of gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976.PubMedGoogle Scholar
  102. 102.
    Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473–479.PubMedGoogle Scholar
  103. 103.
    Bircher J, Muller J, Guggenheim P, Haemmerli UP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet. 1966;1:890–892.PubMedGoogle Scholar
  104. 104.
    Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573–583.PubMedGoogle Scholar
  105. 105.
    Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23:398–406.PubMedGoogle Scholar
  106. 106.
    Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol. 1994;368:125–134.PubMedGoogle Scholar
  107. 107.
    Green PH, Tall AR. Drugs, alcohol and malabsorption. Am J Med. 1979;67:1066–1076.PubMedGoogle Scholar
  108. 108.
    de Melo RT, Charneski L, Hilas O. Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm. 2008;65:818–822.PubMedGoogle Scholar
  109. 109.
    Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081.PubMedGoogle Scholar
  110. 110.
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–908.PubMedGoogle Scholar
  111. 111.
    D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.PubMedGoogle Scholar
  112. 112.
    Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101:506–512.PubMedGoogle Scholar
  113. 113.
    Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017–1022.PubMedGoogle Scholar
  114. 114.
    Murray KF, Carithers RL Jr. AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–1432.PubMedGoogle Scholar
  115. 115.
    Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: “too well for transplant, too sick for life”. JAMA. 2006;295:2168–2176.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Liver Diseases, The Mount Sinai Medical CenterMount Sinai School of MedicineNew YorkUSA

Personalised recommendations